Pleneva (BGC20-0134)

I removed “Pleneva (aka BGC20-0134) (BTG)” from the phase 2 list based on BTG’s Interim Results from September 2011, where they stated, “The development of BGC20-0134 (Pleneva), a potential licensing candidate, was halted following a Phase II study in which it did not meet the primary or secondary endpoints in a study in multiple sclerosis patients.”

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: